ProQR Therapeutics (PRQR) Earns Outperform Rating from Analysts at Evercore ISI

Share on StockTwits

Equities research analysts at Evercore ISI started coverage on shares of ProQR Therapeutics (NASDAQ:PRQR) in a research note issued to investors on Tuesday, September 18th, Marketbeat.com reports. The brokerage set an “outperform” rating and a $35.00 price target on the biopharmaceutical company’s stock. Evercore ISI’s price target indicates a potential upside of 101.15% from the company’s current price.

Other analysts have also issued research reports about the stock. ValuEngine lowered shares of ProQR Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 30th. Chardan Capital restated a “buy” rating and set a $9.00 price target on shares of ProQR Therapeutics in a research note on Monday, August 13th. HC Wainwright set a $20.00 price target on shares of ProQR Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 9th. Finally, Zacks Investment Research upgraded shares of ProQR Therapeutics from a “hold” rating to a “buy” rating and set a $8.00 price target for the company in a research note on Thursday, August 9th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. ProQR Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $18.00.

PRQR stock traded down $0.01 during midday trading on Tuesday, reaching $17.40. 110,242 shares of the company’s stock traded hands, compared to its average volume of 195,719. The firm has a market capitalization of $745.89 million, a PE ratio of -8.97 and a beta of 0.38. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.26. ProQR Therapeutics has a 52 week low of $2.75 and a 52 week high of $22.85.

ProQR Therapeutics (NASDAQ:PRQR) last announced its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.42) by $0.15. On average, equities analysts predict that ProQR Therapeutics will post -1.38 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Millennium Management LLC purchased a new position in ProQR Therapeutics during the 2nd quarter worth $1,426,000. Ardsley Advisory Partners purchased a new position in ProQR Therapeutics during the 2nd quarter worth $365,000. Jennison Associates LLC boosted its holdings in ProQR Therapeutics by 1.0% during the 2nd quarter. Jennison Associates LLC now owns 2,981,205 shares of the biopharmaceutical company’s stock worth $21,763,000 after acquiring an additional 30,831 shares during the last quarter. Essex Investment Management Co. LLC purchased a new position in ProQR Therapeutics during the 2nd quarter worth $604,000. Finally, Franklin Street Advisors Inc. NC boosted its holdings in ProQR Therapeutics by 50.0% during the 2nd quarter. Franklin Street Advisors Inc. NC now owns 90,000 shares of the biopharmaceutical company’s stock worth $657,000 after acquiring an additional 30,000 shares during the last quarter. 28.72% of the stock is currently owned by hedge funds and other institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.

Read More: Earnings Reports

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply